United States v. Pfizer Inc.

560 F.2d 319
CourtCourt of Appeals for the Eighth Circuit
DecidedJuly 18, 1977
DocketNo. 77-1088
StatusPublished
Cited by7 cases

This text of 560 F.2d 319 (United States v. Pfizer Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Eighth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States v. Pfizer Inc., 560 F.2d 319 (8th Cir. 1977).

Opinion

PER CURIAM.

Appellants-defendants, Pfizer Inc. (Pfizer), American Cyanamid Company (Cyan-amid), Bristol-Myers Company (Bristol), Squibb Corporation (Squibb), and the Upjohn Company (Upjohn), appeal from an order1 by the United States District Court for the District of Minnesota (Judge Miles W. Lord), granting the motion of the plaintiff, United States, that this case, having previously been tried to a jury until the district court declared a mistrial, should now be retried to the court alone. This order has been certified for appellate review pursuant to 28 U.S.C. § 1292(b). We [321]*321reverse and direct that the case be retried before judge and jury.

The history of this lengthy litigation has been related in other cases which have come before us. United States v. Lord, 542 F.2d 719, 720-23 (8th Cir. 1976); Pfizer Inc. v. Lord, 456 F.2d 532, 533-35 (8th Cir.), cert. denied, 406 U.S. 976, 92 S.Ct. 2411, 32 L.Ed.2d 676 (1972).2 The district court gave the following procedural history leading to the Government’s motion for a nonjury trial:

[ 0 ]n July 15, 1969, the government filed the above action in the District of Columbia. The complaint contained three counts. Count I is an equitable claim for cancellation of the Conover Patent, the product and process patent on tetracycline. Count II, which the Court has since dismissed, see, e. g., Memorandum and Order Granting Summary Judgment on Count II, dated October 29, 1976, was a common law action of deceit originally against two of the principle defendants, American Cyanamid Co. and Pfizer, Inc. Count III is an antitrust count wherein it is alleged that all five defendants conspired to and did monopolize and restrain trade in the purchase and sale of broad spectrum antibiotics. On September 25, 1969, all of the defendants in the above action filed answers. No demand for a jury trial was filed by any of the defendants within ten days as required by Rule 38, F.R.Civ.Pr. The government has never demanded a jury trial. [Emphasis added.]
On January 30, 1970, the Judicial Panel on Multidistrict litigation transferred Counts II and III of the government’s complaint to the Southern District of New York for coordinated pretrial proceedings. At that time, the panel denied a motion to transfer Count I. On May 17, 1971, Counts II and III of the United States Government’s complaint, together with a large group of other nonsettling cases, were ordered transferred upon completion of discovery to the District of Minnesota, for trial pursuant to 28 U.S.C. 1404(a), see, Administrative Order No. 71-5, May 17, 1971. On July 20, 1971, Count I of the government’s complaint was transferred to the District of Minnesota pursuant to Rule 1404(a). On August 4, 1971, the Court transferred Counts II and III to the District of Minnesota “effective immediately.” See, Administrative Order No. 71-10.
After the transfer to Minnesota, defendants moved the Court for an order granting them a jury trial upon each Count of the complaint in which the defendant was named. The motion was briefed by all parties and taken under advisement by this Court.
The government has made three separate motions to amend its complaint. These motions were made on January 18, 1974, May 30, 1974, and August 25, 1975. The substance of the amendments will be discussed more fully infra. All the motions to amend were granted, and the government filed its third supplemental and amended complaint in October of 1975. In that same month, the defendants each filed amended and supplemental answers. Each amended and supplemental answer demanded a jury trial.
In November of 1974, this case plus five other cases were consolidated for trial. The other five cases all had timely demands for a jury trial by the defendants. Since the Court was required to try the other five cases to a jury, the government case was also to be a jury trial' for Counts II and III. This Court reserved [322]*322the right to determine at a time later in the trial whether Count I would be submitted to the jury.
On August 16,1976, the Court declared a mistrial and discharged the remaining jurors. By this time, the United States Government was the only ease remaining. The question presently before the Court is whether or not upon resumption of the trial the defendants are entitled to a jury. All parties are in agreement that the defendants did not make a timely demand pursuant to Rule 38(b) of the Fed. R.Civ.P. for a jury trial within ten days of the last pleading after service of the original complaint. [Footnotes omitted.]

The appellants, in seeking reversal, contend that (1) the decision not to demand a jury trial on issues raised by the complaint filed in the federal district court for the District of Columbia did not affect the rights of the appellants-defendants to demand a jury trial upon transfer of the case to Minnesota; (2) the district court for the District of Minnesota, having granted these drug companies a right to trial by jury, cannot now deprive them of that right; (3) the district court abused its discretion in denying appellants a jury trial under the circumstances of the case, and (4) appellants have preserved the right to a jury trial by appropriate demands made in answers responding to the Government’s amended complaint.

The district court, in rejecting these contentions, emphasized that considerations of judicial economy require that retrial of this case should be by the court. The district court’s opinion stated:

There has been one and a half years of trial already in this action. The issues are complex and difficult to understand. The Court has been exposed to them once, and has what it considers to be a good grasp of the evidence presented to date. The jury would have to be impaneled, educated, and as happened before, kept away from the publicity which has already caused one mistrial. Many of these problems could be avoided if this case is tried to the Court. A trial to the Court will also significantly shorten the litigation and be a more effective exercise of judicial economy.

We find it necessary to address only the abuse of discretion issue, and hold that under the circumstances of this case the court should have denied the Government’s motion for a bench trial.

The record in this case discloses that the district court has participated in settlement negotiations to an extraordinary degree. We documented, in an earlier case, the district court’s role in initially dissuading the Government from entering into a settlement with the drug companies. Pfizer Inc. v. Lord, supra, 456 F.2d 532. In that case, these appellants unsuccessfully sought mandamus relief to disqualify the district judge. In denying relief, we noted that the district judge’s comments may well “have unnecessarily shaken petitioners’ [appellants’] confidence in his impartiality,” id.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

In Re Tri-State Ethanol Co., LLC
369 B.R. 481 (D. South Dakota, 2007)
In re Appeals from Orders of the Bankruptcy Court
2007 DSD 9 (D. South Dakota, 2007)
Reiter v. Sonotone Corporation
579 F.2d 1077 (Eighth Circuit, 1978)
Reiter v. Sonotone Corp.
579 F.2d 1077 (Eighth Circuit, 1978)
United States v. Pfizer Inc.
560 F.2d 326 (Eighth Circuit, 1977)

Cite This Page — Counsel Stack

Bluebook (online)
560 F.2d 319, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-v-pfizer-inc-ca8-1977.